FDA Regulated Study of Cord Blood Stem Cells to Treat Acquired Hearing Loss Launches

Cord Blood Registry® (CBR®), the world’s largest and most experienced newborn stem cell company, announces the start of a U.S. Food and Drug (FDA)-regulated study being conducted at Florida Hospital for Children in Orlando to investigate the use of a child’s stem cells from their own stored umbilical cord blood as a treatment for acquired sensorineural hearing loss.

Link: http://www.digitaljournal.com/pr/1685758